RETEVMO Drug Patent Profile
✉ Email this page to a colleague
When do Retevmo patents expire, and what generic alternatives are available?
Retevmo is a drug marketed by Loxo Oncol Eli Lilly and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and thirty-four patent family members in forty-one countries.
The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.
DrugPatentWatch® Generic Entry Outlook for Retevmo
Retevmo was eligible for patent challenges on May 8, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 10, 2037. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RETEVMO?
- What are the global sales for RETEVMO?
- What is Average Wholesale Price for RETEVMO?
Summary for RETEVMO
| International Patents: | 134 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Clinical Trials: | 5 |
| Patent Applications: | 45 |
| Drug Prices: | Drug price information for RETEVMO |
| What excipients (inactive ingredients) are in RETEVMO? | RETEVMO excipients list |
| DailyMed Link: | RETEVMO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RETEVMO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for RETEVMO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eli Lilly and Company | Phase 2 |
| Massachusetts General Hospital | Phase 2 |
| Southwest Oncology Group | Phase 2 |
Pharmacology for RETEVMO
Paragraph IV (Patent) Challenges for RETEVMO
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RETEVMO | Capsules | selpercatinib | 40 mg and 80 mg | 213246 | 1 | 2024-05-08 |
US Patents and Regulatory Information for RETEVMO
RETEVMO is protected by forty-five US patents and ten FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RETEVMO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RETEVMO
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Crystalline forms
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER
Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY
FDA Regulatory Exclusivity protecting RETEVMO
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷ Sign Up
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | TABLET;ORAL | 218160-001 | Apr 10, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Loxo Oncol Eli Lilly | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RETEVMO
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly Nederland B.V. | Retsevmo | selpercatinib | EMEA/H/C/005375 Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment |
Authorised | no | no | no | 2021-02-11 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RETEVMO
When does loss-of-exclusivity occur for RETEVMO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 9919
Patent: COMPUESTOS PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDA COMO INHIBIDORES DE RET QUINASA
Estimated Expiration: ⤷ Sign Up
Patent: 9920
Patent: COMPUESTOS PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDA COMO INHIBIDORES DE RET QUINASA
Estimated Expiration: ⤷ Sign Up
Patent: 3760
Patent: FORMAS CRISTALINAS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 17342022
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 17342027
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 18348161
Patent: Crystalline forms
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2019007143
Patent: compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
Estimated Expiration: ⤷ Sign Up
Patent: 2019007144
Patent: compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
Estimated Expiration: ⤷ Sign Up
Patent: 2020005463
Patent: formas cristalinas
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 39760
Patent: COMPOSES SUBSTITUES DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 39912
Patent: COMPOSES DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUES EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 79012
Patent: FORMES CRISTALLINES (CRYSTALLINE FORMS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 19000941
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
Estimated Expiration: ⤷ Sign Up
Patent: 19000942
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
Estimated Expiration: ⤷ Sign Up
China
Patent: 0177786
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 0382494
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 1278822
Patent: 结晶形式 (CRYSTALLINE FORMS)
Estimated Expiration: ⤷ Sign Up
Patent: 4163437
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (Substituted pyrazolo [1, 5-a] pyridine compounds as RET kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 19004649
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
Estimated Expiration: ⤷ Sign Up
Patent: 19004650
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 190218
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 190224
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0201008
Estimated Expiration: ⤷ Sign Up
Patent: 0221154
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 23201
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 019000090
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Patent: 019000091
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 19032676
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Patent: 19033052
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 5568
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ (SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 7208
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ (SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 1990939
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
Estimated Expiration: ⤷ Sign Up
Patent: 1990940
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
Estimated Expiration: ⤷ Sign Up
Patent: 2090695
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 23301
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 94854
Patent: FORMES CRISTALLINES (CRYSTALLINE FORMS)
Estimated Expiration: ⤷ Sign Up
Patent: 53939
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 44735
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 51424
Estimated Expiration: ⤷ Sign Up
Patent: 60089
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 5916
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 5918
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 3730
Patent: צורות גבישיות (Crystalline forms)
Estimated Expiration: ⤷ Sign Up
Patent: 7576
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 76446
Estimated Expiration: ⤷ Sign Up
Patent: 45070
Estimated Expiration: ⤷ Sign Up
Patent: 75399
Estimated Expiration: ⤷ Sign Up
Patent: 79303
Estimated Expiration: ⤷ Sign Up
Patent: 11654
Estimated Expiration: ⤷ Sign Up
Patent: 02365
Estimated Expiration: ⤷ Sign Up
Patent: 19533670
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−Ａ］ピリジン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 20503247
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−Ａ］ピリジン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 20536900
Patent: 結晶形態
Estimated Expiration: ⤷ Sign Up
Patent: 21035944
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−Ａ］ピリジン化合物 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 22062168
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５－Ａ］ピリジン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 22116108
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５－Ａ］ピリジン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 23134580
Patent: ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５－Ａ］ピリジン化合物 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 0190076
Patent: مركبات بيرازولو [1، 5-A]بيريدين بها استبدال كمثبطات كيناز RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 0190077
Patent: مركبات بيرازولو [1، 5-A]بيريدين بها استبدال كمثبطات كيناز RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 5573
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 19004204
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 19004205
Patent: COMPUESTOS DE PIRAZOLO[1,5-4]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 20003552
Patent: FORMAS CRISTALINAS. (CRYSTALLINE FORMS.)
Estimated Expiration: ⤷ Sign Up
Patent: 20011250
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Moldova, Republic of
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 462
Patent: Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
Estimated Expiration: ⤷ Sign Up
Patent: 463
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
Estimated Expiration: ⤷ Sign Up
Patent: 675
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2793
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 190918
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Patent: 191613
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 019500775
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 019500776
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
Saudi Arabia
Patent: 9401541
Patent: [1، 5-A] مركبات بيرازولو كيناز RET بيريدين بها استبدال كمثبطات (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 9401544
Patent: [1، 5-A] مركبات بيرازولو بيريدين بها استبدال كمثبطات كيناز معاد ترتيبه أثناء نقل العدوى (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS REARRANGED DURING TRANSFECTION KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 536
Patent: SUPSTITUISANA PIRAZOLO[1,5-A]PIRIDIN JEDINJENJA KAO INHIBITORI RET KINAZE (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 510
Patent: SUPSTITUISANA PIRAZOLO[1,5-A]PIRIDIN JEDINJENJA KAO INHIBITORI RET KINAZE (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201903144P
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 201903187W
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 23301
Estimated Expiration: ⤷ Sign Up
Patent: 23302
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 2004040
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2143899
Estimated Expiration: ⤷ Sign Up
Patent: 2287752
Estimated Expiration: ⤷ Sign Up
Patent: 2410437
Estimated Expiration: ⤷ Sign Up
Patent: 190076976
Patent: RET 키나제 억제제로서의 치환된 피라졸로[1,5-A]피리딘 화합물
Estimated Expiration: ⤷ Sign Up
Patent: 190077389
Patent: RET 키나제 억제제로서의 치환된 피라졸로[1,5-A]피리딘 화합물
Estimated Expiration: ⤷ Sign Up
Patent: 200051744
Patent: 결정질 형태
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 05087
Estimated Expiration: ⤷ Sign Up
Patent: 26136
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 04148
Estimated Expiration: ⤷ Sign Up
Patent: 52098
Estimated Expiration: ⤷ Sign Up
Patent: 91053
Estimated Expiration: ⤷ Sign Up
Patent: 1825488
Patent: Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 1827428
Patent: Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 1922741
Patent: Crystalline forms
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 19000107
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 19000110
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 5030
Patent: ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ RET-КІНАЗИ (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 5032
Patent: ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ RЕТ-КІНАЗИ (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 925
Patent: FORMAS CRISTALINAS
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RETEVMO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Peru | 20190918 | COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET | ⤷ Sign Up |
| Taiwan | I704148 | ⤷ Sign Up | |
| Cyprus | 1123201 | ⤷ Sign Up | |
| Singapore | 11201903144P | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
